TREM-1 inhibitory peptide GF9
Based on 1 publication(s) in Google Scholar
TREM-1 inhibitory peptide GF9 (Human TREM-1 (213-221)) is a TREM-1 inhibitor. TREM-1 inhibitory peptide GF9 blocks the TREM-1 signaling pathway via a ligand-independent mechanism, spontaneously inserts into the cell membrane to dissociate TREM-1 from DAP-12, and functions through the Signaling Chain Homooligomerization (SCHOOL) model. TREM-1 inhibitory peptide GF9 reduces the levels of TNFα, IL-1β, IL-6, and M-CSF. TREM-1 inhibitory peptide GF9 inhibits tumor growth, prolongs the survival of mice with pancreatic cancer models, ameliorates collagen-induced arthritis, and exerts protective effects on bone and cartilage simultaneously. TREM-1 inhibitory peptide GF9 can be used in research related to arthritis, pancreatic cancer, retinopathy, alcoholic liver disease, and liver cancer.
For research use only. We do not sell to patients.
- Purity: 99.41%
- CAS No.: 1289375-12-7
- Formula: C49H76N10O12
- Molecular Weight:997.19
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) TREM-1 inhibitory peptide GF9
More
Biological Activity
|
TREM-1 |
IL-1β |
IL-6 |
TNF-α |
TREM-1 inhibitory peptide GF9 (incubated for 6 h) colocalizes with TREM-1 on the cell membrane of J774A.1 mouse macrophages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DBA/1 (male, 6-7 weeks old, mean weight 20 g, collagen-induced arthritis model)[1]
-
Dosage:2.5 mg/kg (free GF9, GF9-dHDL, GF9-sHDL); 25 mg/kg (free GF9); 4 mg/kg GF9 equivalent (GA/E31-dHDL, GA/E31-sHDL)
-
Administration:i.p.; daily; 14 days
-
Result:Reduced mean clinical arthritis score to 0.21 on day 38 (25 mg/kg free GF9).
Showed no therapeutic activity at 2.5 mg/kg free GF9.
Achieved therapeutic efficacy comparable to 25 mg/kg free GF9 at 2.5 mg/kg GF9-dHDL and GF9-sHDL.
Reduced clinical arthritis severity at 4 mg/kg GF9 equivalent GA/E31-dHDL and GA/E31-sHDL, with GA/E31-sHDL efficacy comparable to 25 mg/kg free GF9.
Reduced summed histopathology scores by 96% vs. vehicle and 97% vs.
GF9-G (25 mg/kg free GF9).
Reduced inflammation by 94%, pannus formation by 98%, cartilage damage by 96%, bone resorption by 99%, and periosteal bone formation by 98% (25 mg/kg free GF9 vs.
GF9-G).
Reduced histopathology scores by 66-88% vs. vehicle/GF9-G (GF9-dHDL, GF9-sHDL, GA/E31-dHDL, GA/E31-sHDL).
Increased body weight gain to levels comparable to non-arthritic naive mice (all GF9-containing formulations).
Significantly reduced plasma levels of TNFα, IL-1β, IL-6, and M-CSF on days 30 and 38 (25 mg/kg free GF9, 2.5 mg/kg GF9-sHDL, 4 mg/kg GF9 equivalent GA/E31-sHDL).
Chemical Information
-
CAS No. 1289375-12-7
-
Appearance Solid
-
Molecular Weight 997.19
-
Formula C49H76N10O12
-
Color White to off-white
-
Synonyms
Human TREM-1(213-221)
-
Sequence
Gly-Phe-Leu-Ser-Lys-Ser-Leu-Val-Phe
-
Sequence Shortening
GFLSKSLVF
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Adv Res
Targeting mesenchymal monocyte-derived macrophages to enhance the sensitivity of glioblastoma to temozolomide by inhibiting TNF/CELSR2/p65/Kla-HDAC1/EPAS1 axis. [Abstract]2025 May 13:S2090-1232(25)00351-0. PMID: 40373963
Solvent & Solubility
DMSO : 1.92 mg/mL (1.93 mM; ultrasonic and adjust pH to 7 with CH3COOH; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0028 mL | 5.0141 mL | 10.0282 mL | 25.0704 mL |
TREM-1 inhibitory peptide GF9 Related Classifications
HY-P10086 Related Classifications
Powered by Bioz
- TREM-1 inhibitory peptide GF9
- 1289375-12-7
- Human TREM-1(213-221)
- TREM receptor
- TNF Receptor
- Interleukin Related
- c-Fms
- DBA/1 mice
- Triggering receptor expressed on myeloid cells 1
- pro-inflammatory cytokines
- macrophage colony-stimulating factor
- collagen-induced arthritis
- J774A.1 murine macrophages
- Signaling Chain HOmoOLigomerization model
- pancreatic cancer
- TREM-1
- DAP-12
- Inhibitor
- inhibitor
- inhibit